InVision Medical Technology
InVision: AI-powered cardiac ultrasound analysis for enhanced disease detection.
InVision: AI-powered cardiac ultrasound analysis for enhanced disease detection.
InVision Medical Technology was founded with the mission to revolutionize the diagnosis of heart disease through advanced artificial intelligence. The company focuses on developing AI models that streamline the interpretation of cardiac ultrasounds, aiming to identify diseases that may be missed by human readers. Their solutions are seamlessly integrated into clinical workflows, ensuring ease of use for clinicians. InVision targets the healthcare market, particularly cardiology, to enhance diagnostic accuracy and efficiency.
Notable figures affiliated with InVision include leading researchers and clinicians who have contributed to their peer-reviewed publications in prestigious journals such as Nature, Nature Medicine, Lancet Digital Health, and JAMA Cardiology. The company's key achievements include successful results from blinded and randomized clinical trials, demonstrating the efficacy of their AI models. InVision's impact lies in its potential to significantly improve early detection and treatment of heart disease, ultimately aiming to save lives and reduce healthcare costs.
Companies similar to InVision Medical Technology include InvisionHeart, Ainnova Tech, AngioInsight and HeartVista.
InVision Medical Technology was founded in 2022.
InVision Medical Technology's headquarters is located in Los Angeles, CA, US.
InVision Medical Technology's most recent funding round was for $500k (USD) in August 2022.
As of Aug 22, 2022, InVision Medical Technology has disclosed funding of $500k (USD). Undisclosed round amounts are excluded.
InVision Medical Technology has 50 employees as of Feb 24, 2024.
HeartVista
